Vivanza Biosciences Ltd

For the fifth consecutive session, Vivanza Biosciences Ltd closed lower, slipping to a fresh 52-week low of Rs 1.82 on 23 Mar 2026 amid persistent selling pressure that outpaced its sector and the broader market.

Vivanza Biosciences Ltd has witnessed a notable change in its valuation parameters, with its price-to-earnings (P/E) and price-to-book value (P/BV) ratios shifting towards a more attractive zone despite ongoing operational and financial headwinds. This development invites a closer examination of the company’s price attractiveness relative to its historical averages and peer group within the Pharmaceuticals & Biotechnology sector.

Vivanza Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair rating. Despite a modest day gain of 1.02% to close at ₹1.98, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios reveal a complex picture that investors must carefully analyse in the context of sector peers and historical performance.

Vivanza Biosciences Ltd has been downgraded from a Sell to a Strong Sell rating as of 2 March 2026, reflecting deteriorating technical indicators and persistent fundamental weaknesses. Despite some positive quarterly financial results, the company’s long-term performance, valuation metrics, and technical trends have prompted a reassessment of its investment appeal within the Pharmaceuticals & Biotechnology sector.

Vivanza Biosciences Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting a modest improvement in technical indicators amid persistent fundamental challenges. The pharmaceutical and biotechnology company’s overall Mojo Score rose to 34.0, signalling a cautious shift in market sentiment as technical trends show signs of stabilisation despite ongoing financial headwinds.

Vivanza Biosciences Ltd has been downgraded from a Sell to a Strong Sell rating as of 20 Feb 2026, reflecting deteriorating technical indicators and persistent fundamental weaknesses. Despite some positive quarterly financial results, the company continues to underperform its benchmark indices and peers, prompting a reassessment of its investment appeal.

Vivanza Biosciences Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting a notable improvement in valuation metrics and technical indicators despite ongoing challenges in financial trends and quality parameters. The upgrade, effective from 13 February 2026, follows a comprehensive reassessment across four key parameters: Quality, Valuation, Financial Trend, and Technicals.

Vivanza Biosciences Ltd has witnessed a notable transformation in its valuation parameters, shifting from a previously risky profile to one that now appears attractive. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, invites a closer examination of the company’s price attractiveness relative to its historical performance and peer group within the Pharmaceuticals & Biotechnology sector.

Vivanza Biosciences Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹8.00 crores, reported a consolidated net profit of ₹0.20 crores in Q3 FY26 (October-December 2025), marking a dramatic 400.00% year-on-year surge but a concerning 64.29% sequential decline from the previous quarter. The stock traded at ₹2.05 as of February 12, 2026, down 2.38% on the day, reflecting investor caution despite the company's impressive revenue momentum.

Vivanza Biosciences Ltd has been downgraded from a Sell to a Strong Sell rating as of 30 Jan 2026, reflecting deteriorating technical indicators and persistent fundamental challenges. Despite a modest uptick in share price, the company’s long-term financial metrics and technical trends have raised significant concerns for investors.

Vivanza Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently formed a Death Cross, a significant technical indicator where the 50-day moving average crosses below the 200-day moving average. This development signals a potential shift towards a bearish trend, reflecting deteriorating momentum and long-term weakness in the stock’s price action.

Vivanza Biosciences Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 13 January 2026, driven primarily by a shift in technical indicators signalling a mildly bullish trend. Despite this upgrade, the company continues to face significant challenges in valuation, financial health, and long-term growth prospects, which temper investor enthusiasm.

Vivanza Biosciences Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 5 January 2026, reflecting deteriorating technical indicators and persistent fundamental weaknesses. Despite a positive quarterly financial performance, the company continues to underperform its benchmark indices and faces significant challenges across valuation, financial trends, and technical outlook.

Vivanza Biosciences Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 31 December 2025, driven primarily by a shift in technical indicators signalling a mildly bullish trend. Despite this upgrade, the company continues to face significant fundamental challenges, including weak long-term financial metrics and persistent underperformance relative to market benchmarks.